AYTU
Aytu BioPharma, Inc.
2.47
-
0.05
1.98%
0 x 0.00
0 x 0.00
bid
ask
0 @ 05:22 AM
2.47+0.00 (0.00%)
Bearish
52
Bullish
149
sentiment
2.45
day range
2.53
1.53
52 week range
3.50
News
...
Profile
...
Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old. The segment also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The Consumer Health segment is involved in the commercialization of over-the-counter medicines, personal care products, and dietary supplements in various categories, such as hair loss, digestive health, urological health, diabetes management, and allergy. The segment offers Regoxidine - for Men and Women, a proprietary over-the-counter aerosol foam that works to treat hair loss in both men and women; and OmepraCareDR and EsomepraCareDR, acid reducers for the treatment of frequent heartburn. It also engages in the development of AR101 (enzastaurin), an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor targeting the treatment of vascular Ehlers-Danlos Syndrome. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Denver, Colorado.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-09-25 | 2024-06 | 0 | N/A | N/A | N/A |
2024-05-15 | 2024-03 | 0 | -0.52 | N/A | N/A |
2024-02-14 | 2023-12 | 0 | -0.04 | N/A | N/A |
2023-11-14 | 2023-09 | 0 | -1.48 | N/A | N/A |
2023-09-27 | 2023-06 | 0 | 0.16 | N/A | N/A |
2023-05-11 | 2023-03 | 0 | -1.93 | N/A | N/A |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-08 | Maxim Group | Upgrade | Buy | |
2023-05-30 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2021-04-15 | CANTRELL GARY V. | Director | 204.09K | Stock Award(Grant) |
2023-06-13 | DISBROW JOSHUA R. | Chief Executive Officer | 71.59K | Purchase |
2023-08-10 | DOCKERY CARL C | Director | 8.94K | Stock Award(Grant) |
2021-04-07 | HECHT BETH P | Director | 9.05K | Stock Award(Grant) |
2023-08-15 | JAIN ABHINAV | Director | 8.00K | Stock Award(Grant) |
2023-08-10 | LIU VIVIAN H | Director | 1.84K | Stock Award(Grant) |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Nantahala Capital Management, LLC | 1.09M | 1.74M | 19.65% |
2023-06-29 | Stonepine Capital Management, LLC | 472.37K | 755.79K | 8.54% |
2023-06-29 | Renaissance Technologies, LLC | 57.32K | 91.72K | 1.04% |
2023-06-29 | Blackrock Inc. | 24.06K | 38.49K | 0.44% |
2023-06-29 | Acadian Asset Management. LLC | 22.54K | 36.06K | 0.41% |
2023-06-29 | Prudential Financial, Inc. | 19.58K | 31.32K | 0.35% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Extended Market Index Fund | 9.99K | 15.99K | 0.18% |
2023-05-30 | Fidelity Extended Market Index Fund | 8.71K | 14.55K | 0.16% |
2023-05-30 | Fidelity Series Total Market Index Fund | 1.59K | 2.66K | 0.03% |
2023-05-30 | Fidelity Total Market Index Fund | 1.59K | 2.65K | 0.03% |
2023-08-30 | iShares Core S&P Total U.S. Stock Market ETF | 1.27K | 2.15K | 0.02% |
Split
...
Split | Date |
---|---|
1 : 20 | 2023-01-06 |
1 : 10 | 2020-12-09 |
1 : 20 | 2018-08-13 |
1 : 20 | 2017-08-29 |
1 : 12 | 2016-07-01 |
82 : 1000 | 2015-06-10 |
This topic has been deleted. Only users with topic management privileges can see it.
-
Healight scam, test kit scam, Josh i would like to have a private meeting with you. POS
-
Im sure he will mention SYNERGIES many times. Complete goof and scammer. I hope his car doesn't get stuck on the tracks
-
Biggest scam in the whole market Josh is #1 goof scammer out there
-
Bring Healight back. You are a scammer
-
Bring back HEALIGHT
-
-
I THINK THE TEST KITS ARE ARRIVING ANY DAY NOW
-
-
-
-
-
-
-
-
-
Aytu BioPharma, Inc. (AYTU) Q3 2024 Earnings Call Transcript
seekingalpha.com • -
Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript
seekingalpha.com • -
Aytu BioPharma, Inc. (AYTU) Q1 2024 Earnings Call Transcript
seekingalpha.com • -
Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results
accesswire.com • -
Best Penny Stocks? 4 Hot Stocks With News This Week
pennystocks.com • -
Aytu BioPharma, Inc. (AYTU) Q4 2023 Earnings Call Transcript
seekingalpha.com •